NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

argenx SE (ARGX) Stock Analysis

argenx SE (ARGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ARGX

$890.05

+$20.33 (+2.34%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARGX with… →

ARGX Key Statistics

As of Oct 21, 2026
Trading
Open
$875.27
Previous Close
$869.72
Day's Range
873.23–892.85
52-Week Range
661.85–1,072.75
Volume
656.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.04
Valuation
Market Cap
$55.97B
P/E Ratio
33.92
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
25.01
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.06
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.53
EPS (ttm)Profit attributable to each share over the last twelve months.
26.24
Financials (FY)
Revenue (FY)
$4.15B+89.64%
Net Income (FY)
$1.29B+55.10%
Profit marginThe share of revenue left as profit after all costs and taxes.
32.27%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
62.89M
1-Year Return
+6.62%
Dividend and dates
Earnings Date
October 22, 2026
Avg Volume
335.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ARGX closed at $890.05, +6.62% over 1 year.

argenx SE (ARGX) has a market capitalization of $55.97B.

In fiscal 2025, ARGX reported revenue of $4.15B.

ARGX Stock Return by Calendar Year

argenx SE (ARGX) return since May 2017: what $10,000 became

1 year
$10,000 $10,662
+6.62%
5 years
$10,000 $30,256
+202.56%
Since May 2017
$10,000 $386,978
+3,769.78%

If you had invested $10,000 in argenx SE (ARGX) at the close on May 18, 2017, the earliest close on record here, it would have been worth $386,978 at the close on October 21, 2026: +3,769.78% in total, +47.38% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+5.84%
2025+36.74%
2024+61.66%
2023+0.42%
2022+8.18%
2021+19.08%
2020+83.21%
2019+67.09%
2018+52.15%
2017 (partial year)+174.52%

As of October 21, 2026.

ARGX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.15B$1.29B31.1%
2024$2.19B$833.04M38.0%
2023$1.23B−$295.05M−24.1%
2022$410.75M−$709.59M−172.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.15B$3.70B$1.05B$1.29B31.1%
2024$2.19B$1.96B−$17.84M$833.04M38.0%
2023$1.23B$1.11B−$420.64M−$295.05M−24.1%
2022$410.75M$381.32M−$723.92M−$709.59M−172.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARGX Valuation vs Biotechnology Median

Median of 608 stocks
MetricARGXBiotechnology medianvs median
P/E33.9216.60104% above
P/S ratio10.5313.3021% below
Profit margin32.27%−38.31%70.6 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values argenx SE (ARGX) at $55.97B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1,863.

ARGX last closed at $890.05 on October 21, 2026. That is +$20.33 (+2.34%) against the previous close. Over the past 52 weeks the price has ranged from $661.85 to $1,072.75. The latest close sits 34.48% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.15B. That is +89.64% against the prior fiscal year, when revenue was $2.19B. The same year closed with net income of $1.29B. That is +55.10% against the prior fiscal year. The reported profit margin is 32.27%. That is 70.6 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 26.24.

Across the 4 fiscal years on file, revenue moves from $410.75M in 2022 to $4.15B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 33.92 times earnings. That is 104.34% above the Biotechnology median of 16.6. The forward P/E on file is 25.01. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.06. The price-to-sales ratio is 10.53. On price-to-sales that is 20.82% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +6.62%. Across 5 years the annualized return works out at +24.79%. Beta against the wider market is reported at −0.04. Annualized volatility over the trailing 9 years is 51.03%.

Growth & Income

The record shows no dividend for ARGX.

2026 is still running; the total return is +5.84% year to date. The strongest complete calendar year on file is 2020 at +83.21%; the weakest is 2023 at +0.42%. Of the 8 complete calendar years on file, 8 finished higher.

Peer Comparison

argenx SE (ARGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
argenx SE ARGX $55.97B 33.9
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. argenx SE trades at a P/E of 33.9.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B

 RPRX

Royalty Pharma plc

$35.91B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Visit website →